NASH

[Journal of Clinical Investigation] The authors provided new insights into the mechanisms that underlied Dyrk1b-induced hepatic lipogenesis and hepatic insulin resistance and identified Dyrk1b as a therapeutic target for non-alcoholic liver steatohepatitis and insulin resistance in the liver.

[Hepion Pharmaceuticals, Inc.] Hepion Pharmaceuticals, Inc. announced that the US FDA has granted Fast Track designation for the Company’s lead drug candidate, CRV431, for the treatment of non-alcoholic steatohepatitis (NASH).

[Experimental and Molecular Medicine] The authors review the biochemical steps of hepatic lipid metabolism, dysregulated lipid metabolism in obesity and nonalcoholic fatty liver disease (NAFLD), and the roles of IκB kinase complexes and TANK-binding kinase 1 in obesity and NAFLD.

[CytoDyn, Inc.] CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reported data from its trial treating nonalcoholic steatohepatitis (NASH) open label with leronlimab.

[EpicentRx, Inc.] EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,906,957 entitled "Immunomodulatory Fusion Proteins."

[Scientific Reports] Investigators presented a 3D in vitro microtissue model that used spheroidal, scaffold free co-culture of primary human hepatocytes, Kupffer cells, liver endothelial cells and hepatic stellate cells.